Picture loading failed.

Anti-PCSK9 therapeutic antibody (Pre-made Lodelcizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Ligelizumab (QGE031) is a humanized monoclonal antibody (mAb) designed for the treatment of severe asthma and chronic spontaneous urticaria. his drug was developed by Novartis Pharma AG. As of 2018, ligelizumab is undergoing Phase III trials. It binds with high affinity to the Cε3 domain of IgE.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-318-1mg 1mg 3090
GMP-Bios-ab-318-10mg 10mg 21890
GMP-Bios-ab-318-100mg 100mg 148000
GMP-Bios-ab-318-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-PCSK9 therapeutic antibody (Pre-made Lodelcizumab biosimilar,Whole mAb)
INN Name Lodelcizumab
TargetPCSK9
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2012
Year Recommended2013
CompaniesNovartis
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedHypercholesterolaemia
Development Techna